Somnus submits 510(k) for Somnoplasty RF ablation system for habitual snoring.
This article was originally published in The Gray Sheet
Executive SummarySOMNUS 510(k) FOR SOMNOPLASTY ABLATION SYSTEM TO TREAT HABITUAL SNORING was submitted to FDA the week of April 14, the company says. The submission includes data from a 40-patient study conducted at the Stanford University Medical Center that evaluates use of Somnus Medical Technologies' Somnoplasty system for reducing snoring.
You may also be interested in...ï»¿
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sareptaâ€™s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.